Programmable Nanocarrier-Based Targeted Cellular Delivery of Shiga Toxin A Subunit Effector Polypeptides

A next-generation targeted cellular delivery system utilizing programmable nanocarriers and optimized cell-targeting molecules to enhance the efficacy and specificity of Shiga toxin A subunit effector polypeptide-based therapies.

The original patent disclosed cell-targeting molecules comprising Shiga toxin effector polypeptides, but these molecules had limitations in terms of delivery efficiency and specificity. The new inventive concept addresses these limitations by introducing programmable nanocarriers that can be tailored to specific cell types, thereby enhancing the targeted delivery of Shiga toxin A subunit effector polypeptides.

The new inventive concept comprises a system for targeted cellular delivery of Shiga toxin A subunit effector polypeptides, featuring a nanocarrier with a programmable surface chemistry and a cell-targeting molecule conjugated to the nanocarrier. The cell-targeting molecule is configured to selectively bind to a specific cell type and facilitate uptake of the nanocarrier. The nanocarrier can be a liposome with a dynamic lipid bilayer composition, allowing for real-time optimization of the surface chemistry. The cell-targeting molecule can be generated through a high-throughput, microfluidics-based assay, enabling rapid screening and selection of variants with improved binding affinity and specificity.

The new claims introduce the concept of programmable nanocarriers, which is a significant departure from the original patent's focus on cell-targeting molecules alone. The combination of programmable nanocarriers and optimized cell-targeting molecules provides a novel and non-obvious solution for targeted cellular delivery of Shiga toxin A subunit effector polypeptides.

Alternative embodiments of the inventive concept could include the use of different types of nanocarriers, such as nanoparticles or viral vectors, or the incorporation of additional functional elements, such as imaging agents or therapeutic payloads. Variations of the cell-targeting molecule could include different Shiga toxin effector polypeptide variants or alternative binding regions.

The inventive concept has significant commercial potential in the development of targeted therapies for various diseases, including cancer and inflammatory disorders. The ability to selectively deliver Shiga toxin A subunit effector polypeptides to specific cell types could lead to improved treatment outcomes and reduced side effects. The market for targeted therapies is growing rapidly, with an estimated value of over $10 billion by 2025.